Amjevita FDA Approval History
FDA Approved: Yes (First approved September 23, 2016)
Brand name: Amjevita
Generic name: adalimumab-atto
Dosage form: Injection
Previous Name: ABP 501
Company: Amgen Inc.
Treatment for: Plaque Psoriasis, Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohn's Disease, Maintenance, Psoriatic Arthritis, Juvenile Idiopathic Arthritis
Amjevita (adalimumab-atto) an anti-TNF-α monoclonal antibody biosimilar to Humira, approved for the treatment of various inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.
The FDA approval of Amjevita was based on analytical, nonclinical, pharmacokinetic and clinical data supporting biosimilarity to the reference product Humira. Safety and immunogenicity were also comparable.
Amjevita is administered via subcutaneous injection.
Amjevita comes with a Boxed Warning alerting health care professionals and patients of the increased risk of serious infections and malignancies. The most common reported side effects include infections (including upper respiratory, sinusitis), injection site reactions, headache, and rash.
Development Timeline for Amjevita
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
